Ascelia Pharma’s share price rose by 3,55% yesterday, following the final outcome of the rights issue released before closure. The company has secured approximately SEK 105 million in gross proceeds before issue costs. The issue was completed without guarantors. This positive outcome reduces the financial uncertainty for Ascelia Pharma and enables the company to continue with the FDA submission process for Orviglance, advance discussions with potential commercial partners ahead of the launch, and amortize SEK 7.5 million of convertible debt to Fenja Capital (Formue Nord), thereby strengthening the balance sheet. The timetable for NDA submission to FDA for Orviglance: Q4-2024: Full Phase-3 - Orviglance study report Q1-2025: Conclusions from the FDA pre-submission meeting Mid-2025: FDA submission.  Ascelia Pharma will report its Q3 results on November 7, 2024.  Link to full announcement here:Ascelia Pharma announcement For an update on Ascelia Pharma prior to trading in the rights issue, listen to the interview with Deputy CEO Julie Waras Brogren here: Interview with Deputy CEO Julie Waras Brogren  Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup  8:00 AM 06-09-2024.

info@inderes.fi (inderes.fi)

© Inderes Oyj. All rights reserved.